For three decades, a drug intended for long-term use carried a near-automatic nonclinical line item: a two-year rat carcinogenicity bioassay, run late in development, expensive, slow, and rarely dispositive on its own. The ICH S1B(R1) Addendum, endorsed by ICH's regulatory members on August 4, 2022, gave sponsors a different option: build a weight-of-evidence case across six factors, and skip the rat study if the case shows it would not change the human carcinogenic-risk conclusion. Four years in, the most common mistake is not misreading the six factors — it is treating the addendum as a blanket exemption from the carcinogenicity question rather than a different way of answering it.
What changed, and what didn't
Before the addendum, ICH S1B called for an assessment of carcinogenic potential — typically a 2-year rat bioassay paired with either a 2-year mouse study or a shorter alternative model, commonly the six-month rasH2 transgenic mouse assay — for drugs with special cause for concern or intended for long-term use. The rat bioassay in particular drew criticism for years: it is slow, costly, and its positive and negative findings often correlate poorly with actual human carcinogenic risk. S1B(R1) did not eliminate the underlying question. It added a second, prospective pathway to answer it — a weight-of-evidence case that can substitute for the rat study specifically, decided on existing data rather than a new two-year study.
The six factors are a case, not a checklist
The weight-of-evidence assessment asks whether the existing nonclinical and clinical pharmacology package already answers the carcinogenicity question well enough that a dedicated two-year rat study would not change the conclusion:
- Target biology. Whether the drug's pharmacological target is mechanistically linked to cell proliferation, tumor suppression, or other carcinogenesis-relevant pathways.
- Secondary pharmacology. Off-target receptor or enzyme activity from broader screening panels that could independently raise carcinogenic concern.
- Histopathology from chronic toxicity studies. Proliferative or pre-neoplastic findings already observed in repeat-dose studies the sponsor has run for other reasons.
- Hormonal perturbation. Sustained changes to hormone levels that are a recognized mechanism for certain tumor types.
- Genotoxicity. Results from the standard genotoxicity battery, which remains a required input regardless of which carcinogenicity pathway a sponsor takes.
- Immune modulation. Immunosuppressive or immune-activating effects with known associations to malignancy risk.
A single adverse signal in one factor does not automatically defeat the case, and six quiet factors do not automatically make one. The addendum asks for an integrated judgment, not a scorecard. Why sponsors misapply the six-factor test
What the addendum left alone
Two things the addendum does not touch are the ones sponsors most often assume it does. First, the mouse carcinogenicity assessment — the short-term or transgenic model ICH S1B already called for — is untouched; a weight-of-evidence case against the rat bioassay says nothing about whether the mouse study is also unnecessary, and teams that fold the two together into one waiver request build a program gap regulators will flag. Second, the underlying obligation to assess carcinogenic potential for long-duration or special-concern drugs has not changed; S1B(R1) changes how that assessment can be built, not whether it is required. The addendum is closer in spirit to ICH S9's anticancer waivers — a defined, data-driven off-ramp from a specific default study — than to a general relaxation of nonclinical expectations.
- Start the inventory early. The six factors draw on data from studies already in the program — secondary pharmacology screens, chronic-study histopathology, the genotoxicity battery — so the case can take shape well before a go/no-go decision on the rat study is due.
- Treat ambiguous factors honestly. A factor that reads as neutral-to-concerning is a reason to strengthen the case with additional analysis, not a reason to omit it from the submission.
- Raise the case with regulators before the clock runs out. Bringing the weight-of-evidence rationale to FDA or EMA only after the rat study's conduct window has passed converts a planning decision into a program delay.
- Keep the mouse track moving regardless. Schedule the mouse carcinogenicity assessment on its own timeline so it is never contingent on how the rat bioassay question resolves.
None of this is a reason to treat S1B(R1) cautiously — for a meaningful share of programs, the existing data genuinely does answer the rat-bioassay question, and running a two-year study anyway wastes development time the addendum was built to recover. The failure mode is narrower: treating the six factors as boxes to check rather than evidence to weigh, or treating a successful rat-bioassay waiver as license to under-scope the rest of the nonclinical carcinogenicity package. Our nonclinical regulatory team builds the weight-of-evidence case against data already in hand and brings it to regulators on a timeline that protects the program if the case does not land — our IND strategy work exists for exactly this sequencing problem.
Frequently asked questions
Does ICH S1B(R1) eliminate the need for carcinogenicity testing?
No. The addendum gives sponsors a route to waive specifically the 2-year rat carcinogenicity bioassay when a weight-of-evidence case shows it would not add value to the human risk assessment. It does not remove the underlying requirement to assess carcinogenic potential for drugs with special cause for concern or intended for long-term use, and it leaves the mouse carcinogenicity assessment in place.
Which six factors make up the weight-of-evidence assessment?
Target biology, secondary pharmacology, histopathological findings from chronic toxicity studies, hormonal perturbation, genotoxicity, and immune modulation. The case is built from data a sponsor typically already has in hand from its standard nonclinical program, not from a dedicated new study.
Does the addendum affect the mouse carcinogenicity study too?
No. ICH S1B(R1) is specific to the rat bioassay decision. The standard short-term or transgenic mouse carcinogenicity model that ICH S1B already called for — commonly a six-month rasH2 study — is unchanged by the addendum and still needs to be addressed separately.
Sources & further reading
- ICH. S1B(R1) Addendum to S1B Testing for Carcinogenicity of Pharmaceuticals (Step 4, endorsed August 4, 2022). database.ich.org
- FDA. S1B(R1) Addendum to S1B Testing for Carcinogenicity of Pharmaceuticals — guidance for industry. fda.gov
This article is provided for general informational purposes and reflects the regulatory landscape as of October 2026. It is not legal or regulatory advice. Confirm current ICH S1B(R1) expectations and regional adoption status with FDA, EMA, or qualified counsel before acting.
